JANX on Nasdaq
Janux Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in Delaware1
In its 2026 annual report the company says: “We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming the liabilities associated with prior generations of TCEs.”3 It is headquartered in San Diego, California.1 Its shares trade on Nasdaq under the symbol JANX.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Zenas BioPharma, Inc., Spectrum Pharmaceuticals or PROTHENA CORP PUBLIC LTD CO, or pick any stock.
- TickerJANX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSan Diego, California1
- Incorporated inDE2
- Business address10955 Vista Sorrento Parkway, Suite 200, San Diego, Ca 921302
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
We are an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying our proprietary technologies to our Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. The goal of our TRACTr and TRACIr platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Our initial focus is on developing a novel class of TRACTr therapeutics designed to target clinically validated TCE drug targets, while overcoming…3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-1576.7%Operating margin4
-1136.2%Net margin4
-5.6%Revenue growth, 20254
-11.9%Return on equity4
-$83.3MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$125.9M
Out of $10.0M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Collaboration revenue | $10.0M | $10.6M | $8.1M |
| Research and development | $125.9M | $68.4M | $54.9M |
| General and administrative | $41.8M | $41.0M | $26.1M |
| Total operating expenses | $167.7M | $109.4M | $81.1M |
| Loss from operations | -$157.7M | -$98.8M | -$73.0M |
| Interest income | $44.0M | $29.9M | $14.7M |
| Total other income | $44.0M | $29.9M | $14.7M |
| Net loss | -$113.6M | -$69.0M | -$58.3M |
| Unrealized gain on available-for-sale securities, net | $2.2M | $1.5M | $2.2M |
| Comprehensive loss | -$111.5M | -$67.5M | -$56.1M |
| Net loss per common share, basic | -$1.83 | -$1.28 | -$1.32 |
| Net loss per common share, diluted | -$1.83 | -$1.28 | -$1.32 |
| Weighted-average shares of common stock outstanding, basic | 62.0M shares | 53.8M shares | 44.0M shares |
| Weighted-average shares of common stock outstanding diluted | 62.0M shares | 53.8M shares | 44.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $52.3M | $430.6M | ||
| Short-term investments | $914.2M | $594.6M | ||
| Prepaid expenses and other current assets | $9.3M | $8.5M | ||
| Total current assets | $975.9M | $1.0B | ||
| Restricted cash | $816.0K | $816.0K | ||
| Property and equipment, net | $3.9M | $4.9M | ||
| Operating lease right-of-use assets | $18.4M | $19.3M | ||
| Other long-term assets | $2.6M | $2.9M | ||
| Total assets | $1.0B | $1.1B | ||
| Accounts payable | $5.0M | $4.0M | ||
| Accrued expenses | $17.6M | $11.7M | ||
| Current portion of operating lease liabilities | $2.4M | $1.7M | ||
| Total current liabilities | $25.0M | $17.5M | ||
| Operating lease liabilities, net of current portion | $19.7M | $21.3M | ||
| Total liabilities | $44.7M | $38.7M | ||
| Common stock, $0.001 par value; authorized shares - 200,000,000 at December 31, 2025 and 2024, respectively; issued shares - 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively; outstanding shares - 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively | $60.0K | $59.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive income | $4.3M | $2.2M | ||
| Accumulated deficit | -$351.4M | -$237.8M | ||
| Total stockholders' equity | $956.8M | $1.0B | $344.3M | $320.7M |
| Total liabilities and stockholders' equity | $1.0B | $1.1B | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued | 60.4M shares | 59.1M shares | ||
| Common stock, shares outstanding | 60.4M shares | 59.1M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $52.3M | $430.6M | ||
| Short-term investments | $914.2M | $594.6M | ||
| Prepaid expenses and other current assets | $9.3M | $8.5M | ||
| Total current assets | $975.9M | $1.0B | ||
| Restricted cash | $816.0K | $816.0K | ||
| Property and equipment, net | $3.9M | $4.9M | ||
| Operating lease right-of-use assets | $18.4M | $19.3M | ||
| Other long-term assets | $2.6M | $2.9M | ||
| Total assets | $1.0B | $1.1B | ||
| Accounts payable | $5.0M | $4.0M | ||
| Accrued expenses | $17.6M | $11.7M | ||
| Current portion of operating lease liabilities | $2.4M | $1.7M | ||
| Total current liabilities | $25.0M | $17.5M | ||
| Operating lease liabilities, net of current portion | $19.7M | $21.3M | ||
| Total liabilities | $44.7M | $38.7M | ||
| Common stock, $0.001 par value; authorized shares - 200,000,000 at December 31, 2025 and 2024, respectively; issued shares - 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively; outstanding shares - 60,384,283 and 59,064,606 at December 31, 2025 and 2024, respectively | $60.0K | $59.0K | ||
| Additional paid-in capital | $1.3B | $1.3B | ||
| Accumulated other comprehensive income | $4.3M | $2.2M | ||
| Accumulated deficit | -$351.4M | -$237.8M | ||
| Total stockholders' equity | $956.8M | $1.0B | $344.3M | $320.7M |
| Total liabilities and stockholders' equity | $1.0B | $1.1B | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 200.0M shares | 200.0M shares | ||
| Common stock, shares issued | 60.4M shares | 59.1M shares | ||
| Common stock, shares outstanding | 60.4M shares | 59.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$113.6M | -$69.0M | -$58.3M |
| Depreciation | $2.0M | $2.1M | $2.0M |
| Stock-based compensation | $40.2M | $33.0M | $20.0M |
| Accretion of discounts on investments, net | -$17.6M | -$10.6M | -$7.7M |
| Prepaid expenses and other current assets | -$827.0K | -$3.3M | $210.0K |
| Other long-term assets | $276.0K | -$375.0K | -$1.1M |
| Accounts payable | $977.0K | $1.6M | $277.0K |
| Accrued expenses | $6.3M | $4.4M | -$678.0K |
| Deferred revenue | $0 | -$1.7M | -$5.9M |
| Operating lease right-of-use assets and liabilities, net | -$2.0K | $35.0K | $678.0K |
| Net cash used in operating activities | -$82.2M | -$43.8M | -$50.6M |
| Purchases of property and equipment | -$1.0M | -$359.0K | -$1.9M |
| Purchases of short-term investments | -$705.2M | -$470.6M | -$317.3M |
| Maturities of short-term investments | $405.3M | $212.9M | $278.0M |
| Net cash used in investing activities | -$301.0M | -$258.0M | -$41.2M |
| Proceeds from exercise of common stock options and employee stock purchase plan | $5.3M | $15.0M | $3.0M |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | -$347.0K | $698.3M | $56.5M |
| Net cash provided by financing activities | $4.9M | $713.2M | $59.5M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$378.3M | $411.4M | -$32.2M |
| Unpaid property and equipment | $0 | $6.0K | $132.0K |
| Unpaid issuance costs | $0 | $347.0K | $0 |
| Vesting of restricted common stock | $0 | $20.0K | $149.0K |
| Unrealized gain on available-for-sale securities, net | $2.2M | $1.5M | $2.2M |
| Operating lease liabilities arising from right-of-use assets | $943.0K | $0 | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
Janux Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Janux Therapeutics, Inc.
- Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Janux Therapeutics, Inc., latest Aug 14, 2026 (3 filings since Apr 29, 2026)
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Janux Therapeutics, Inc., latest Aug 13, 2026 (9 filings since Feb 14, 2022)
- BlackRock Filed SCHEDULE 13G/A on Janux Therapeutics, Inc., latest Jul 28, 2026 (2 filings since Jul 17, 2025)
- State Street Corporation Filed SCHEDULE 13G on Janux Therapeutics, Inc., latest May 12, 2026 (2 filings since Feb 9, 2026)
- FMR LLC Filed SCHEDULE 13G/A on Janux Therapeutics, Inc., latest May 6, 2026 (6 filings since Jan 10, 2022)
- Prosight Management, LP Filed SCHEDULE 13G on Janux Therapeutics, Inc., latest Feb 6, 2026
- Paradigm Biocapital Advisors LP Filed SCHEDULE 13G/A on Janux Therapeutics, Inc., latest Aug 14, 2025 (3 filings since Oct 23, 2024)
- Adage Capital Management, L.P. Filed SCHEDULE 13G/A on Janux Therapeutics, Inc., latest Aug 12, 2025 (2 filings since Feb 12, 2025)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13D/A on Janux Therapeutics, Inc., latest Mar 10, 2025 (4 filings since Mar 6, 2024)
- BIOTECHNOLOGY VALUE FUND L P Filed SC 13G/A on Janux Therapeutics, Inc., latest Nov 14, 2024 (3 filings since May 30, 2023)
- CITADEL ADVISORS LLC Filed SC 13G/A on Janux Therapeutics, Inc., latest Nov 14, 2024 (3 filings since Jul 10, 2023)
- David Alan Campbell Filed SC 13G/A on Janux Therapeutics, Inc., latest Nov 14, 2024 (4 filings since Feb 11, 2022)
- Janux Therapeutics, Inc. San Diego, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Janux Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $10.8M4 Dec 31, 2025 | $9.8M4 Dec 31, 2024 | +10.2% |
| Accumulated depreciation | $7.0M4 Dec 31, 2025 | $5.0M4 Dec 31, 2024 | +40.7% |
| Property and equipment, net | $3.9M4 Dec 31, 2025 | $4.9M4 Dec 31, 2024 | −20.8% |
| Operating-lease assets (leased space) | $18.4M4 Dec 31, 2025 | $19.3M4 Dec 31, 2024 | −4.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $52.3M4 Dec 31, 2025 | $430.6M4 Dec 31, 2024 | −87.8% |
| Marketable securities, current | $914.2M4 Dec 31, 2025 | $594.6M4 Dec 31, 2024 | +53.8% |
| Debt securities available for sale | $914.2M4 Dec 31, 2025 | $594.6M4 Dec 31, 2024 | +53.8% |
Properties, in its own words
Our corporate headquarters is located in San Diego, California, where we lease office and laboratory space pursuant to a lease agreement which commenced in July 2022 and expires in January 2033. At the same location, we have a separate sublease for additional office space pursuant to a lease agreement which commenced in August 2025 and expires in January 2028. We believe that our existing facilities are adequate for the foreseeable future. As we expand, we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.
Item 2 of the 10-K filed Feb 26, 2026.3
Leadership
Who has led Janux Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2025
- Chief financial officerTighe Reardon Jun 10, 2021 to Jun 5, 202411
Board members and other officers (23)
- Chief Medical OfficerWilliam Go Feb 4, 2026 to now12
- Chief Medical OfficerZachariah McIver Jan 3, 2025 to now13
- Chief Corp. & Bus. Dev. OfcrJaneen Noel Doyle May 23, 2025 to now14
- Chief Scientific OfficerThomas Diraimondo Jan 3, 2024 to now15
- Vice President, AccountingMaria Dobek Aug 9, 2024 to now16
- Chief Technical OfficerCharles M. Winter Jan 5, 2023 to now17
- Chief Strategy OfficerByron Robinson Mar 3, 2022 to Jan 3, 202518
- Chief Business OfficerAndrew Hollman Meyer Jun 10, 2021 to now19
- Chief Medical OfficerWayne Godfrey Jun 10, 2021 to Jan 5, 202320
- Chief Scientific OfficerShahram Salek-Ardakani Jul 20, 2021 to Jan 5, 202221
- Board memberEric Dobmeier Jul 22, 2024 to now22
- Board memberNatasha Hernday Jul 22, 2024 to now23
- Board memberWinston Kung Sep 22, 2022 to now24
- Board memberJake Simson Jun 10, 2021 to now25
- Board memberJay Lichter Jun 10, 2021 to Jun 28, 202426
- Board memberPeter A. Thompson Jun 10, 2021 to Jun 16, 202227
- Board memberPeter Kolchinsky Jun 10, 2021 to now28
- Board memberRajeev M. Shah Jun 10, 2021 to now28
- Board memberSheila Gujrathi Jun 10, 2021 to now29
- Board memberStefan Heller Jun 10, 2021 to Jun 16, 202230
- Board memberVickie L. Capps Jun 10, 2021 to now31
- Board memberAlana B. McNulty Sep 9, 2021 to now32
- Board memberRonald W. Barrett Sep 9, 2021 to now33
Timeline
- Aug 6, 20268-K Results of operations34
- Jun 23, 20268-K Other events35
- Jun 12, 20268-K Shareholder vote36
- May 7, 20268-K Results of operations37
- Apr 28, 20268-K Executive or director change38
- Feb 26, 20268-K Results of operations39
- Jan 22, 20268-K Entered a material agreement; Regulation FD disclosure40
- Nov 6, 20258-K Results of operations41
- Sep 19, 20258-K Executive or director change42
- Aug 7, 20258-K Results of operations43
- Jun 13, 20258-K Shareholder vote44
- May 8, 20258-K Results of operations45
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.39) a share, on Nov 6, 2025.46
When it reported results
- Aug 6, 2026Reported quarterly or annual results34
- May 7, 2026Reported quarterly or annual results37
- Feb 26, 2026Reported quarterly or annual results39
- Nov 6, 2025Reported quarterly or annual results41
- Aug 7, 2025Reported quarterly or annual results43
- May 8, 2025Reported quarterly or annual results45
- Feb 27, 2025Reported quarterly or annual results47
- Nov 6, 2024Reported quarterly or annual results48
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
380 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 137 insider forms, 55 large holders, 124 other. The latest 20:
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 31, 20264 EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 10, 20264 EDGAR
- Jun 23, 20268-K EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20268-K EDGAR
- Jun 4, 20264 EDGAR
- Jun 2, 2026144 EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 13, 20264 EDGAR
The 380 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
52 open-market trades by officers, directors and large owners since October 2021: 8 buys and 44 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | Sale | 4,059 | $14.03 | $56.9K | Form 4 |
| May 11, 2026 | Dobek MariaVice President, Accounting | Sale | 2,038 | $14.17 | $28.9K | Form 4 |
| Jan 2, 2026 | McIver ZachariahChief Medical Officer | Sale | 2,714 | $13.73 | $37.3K | Form 4 |
| Jan 2, 2026 | Dobek MariaVice President, Accounting | Sale | 1,462 | $13.73 | $20.1K | Form 4 |
| Jan 2, 2026 | DiRaimondo ThomasChief Scientific Officer | Sale | 2,505 | $13.73 | $34.4K | Form 4 |
| Jan 2, 2026 | Winter Charles M.Chief Technical Officer | Sale | 2,401 | $13.73 | $33.0K | Form 4 |
| Jan 2, 2026 | Meyer Andrew HollmanChief Business Officer | Sale | 1,879 | $13.73 | $25.8K | Form 4 |
| Jan 2, 2026 | Campbell David AlanPresident and CEO | Sale | 8,072 | $13.73 | $110.8K | Form 4 |
| Dec 1, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 3,333 | $32.98 | $109.9K | Form 4 |
| Nov 14, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 3,333 | $30.00 | $100.0K | Form 4 |
| Oct 28, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 16,665 | $30.06 | $500.9K | Form 4 |
| May 1, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 3,333 | $32.03 | $106.7K | Form 4 |
| Apr 21, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 3,334 | $30.00 | $100.0K | Form 4 |
| Mar 7, 2025 | RA Capital Healthcare Fund LPDirector | Buy | 110,206 | $31.02 | $3.4M | Form 4 |
| Mar 6, 2025 | RA Capital Healthcare Fund LPDirector | Buy | 372,093 | $30.78 | $11.5M | Form 4 |
| Mar 5, 2025 | RA Capital Healthcare Fund LPDirector | Buy | 341,742 | $30.64 | $10.5M | Form 4 |
| Mar 3, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 3,334 | $32.14 | $107.2K | Form 4 |
| Feb 3, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 3,334 | $42.29 | $141.0K | Form 4 |
| Jan 7, 2025 | Campbell David AlanPresident and CEO | Sale | 5,000 | $60.00 | $300.0K | Form 4 |
| Jan 2, 2025 | Meyer Andrew HollmanChief Business Officer | Sale | 13,334 | $54.88 | $731.8K | Form 4 |
All 52 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Point72 Asset Management, L.P.SCHEDULE 13G/A, 3 filings Apr 29, 2026 to Aug 14, 202649
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 9 filings Feb 14, 2022 to Aug 13, 202650
- BlackRockSCHEDULE 13G/A, 2 filings Jul 17, 2025 to Jul 28, 202651
- State Street CorporationSCHEDULE 13G, 2 filings Feb 9, 2026 to May 12, 202652
- FMR LLCSCHEDULE 13G/A, 6 filings Jan 10, 2022 to May 6, 202653
- Prosight Management, LPSCHEDULE 13G, 1 filing Feb 6, 202654
- Paradigm Biocapital Advisors LPSCHEDULE 13G/A, 3 filings Oct 23, 2024 to Aug 14, 202555
- Adage Capital Management, L.P.SCHEDULE 13G/A, 2 filings Feb 12, 2025 to Aug 12, 202556
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A, 4 filings Mar 6, 2024 to Mar 10, 202557
- BIOTECHNOLOGY VALUE FUND L PSC 13G/A, 3 filings May 30, 2023 to Nov 14, 202458
- CITADEL ADVISORS LLCSC 13G/A, 3 filings Jul 10, 2023 to Nov 14, 202459
- David Alan CampbellSC 13G/A, 4 filings Feb 11, 2022 to Nov 14, 202460
- Avalon Ventures XI, L.P.SC 13D/A, 7 filings Nov 16, 2023 to Nov 8, 202461
- Bregua CorpSC 13G/A, 2 filings Feb 1, 2024 to Nov 4, 202462
- ORBIMED ADVISORS LLCSC 13D/A, 2 filings Dec 17, 2021 to Aug 9, 202463
- EcoR1 Capital, LLCSC 13G/A, 2 filings Jan 23, 2023 to Feb 14, 202464
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | David CampbellPh.D. | $680.0K | $13.5M65 | |
| 2025 | Byron RobinsonPh.D., J.D. | $362.7K | $5.1M65 | |
| 2025 | Janeen DoyleChief Corporate and Business Development Officer | $310.0K | $4.7M65 | |
| 2025 | Zachariah McIver, D.O., Ph.D.Former Chief Medical Officer | $475.0K | $4.6M65 | |
| 2025 | Thomas DiRaimondoPh.D. | $478.0K | $4.3M65 | |
| 2024 | President and Chief Executive Officer | $646.0K | $9.0M65 | |
| 2024 | Former Chief Strategy Officer | $485.0K | $3.8M65 | |
| 2024 | Chief Scientific Officer | $420.0K | $3.4M65 | |
| 2023 | President and Chief Executive Officer | $625.0K | $4.2M65 | |
| 2023 | Former Chief Strategy Officer | $450.0K | $1.7M65 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,189,693 | $171.9M | 1.5% | No change |
| BlackRock, Inc. | 6,134,667 | $94.2M | 0.0% | +701,434 |
| Prosight Management, LP | 3,804,481 | $58.4M | 10.1% | +254,481 |
| State Street Corp | 3,004,899 | $46.2M | 0.0% | +540,882 |
| Fmr LLC | 2,412,825 | $37.1M | 0.0% | −122,899 |
| Federated Hermes, Inc. | 2,352,927 | $36.1M | 0.1% | +2,298,727 |
| Point72 Asset Management, L.P. | 1,993,837 | $30.6M | 0.0% | +837,697 |
| Vanguard Capital Management LLC | 1,857,351 | $28.5M | 0.0% | +45,986 |
| TCG Crossover Management, LLC | 1,789,617 | $27.5M | 0.7% | No change |
| Alyeska Investment Group, L.P. | 1,647,140 | $25.3M | 0.1% | +46,051 |
| Nantahala Capital Management, LLC | 1,619,828 | $24.9M | 0.8% | +809,914 |
| Wellington Management Group Llp | 1,507,360 | $23.2M | 0.0% | −90,290 |
| Vanguard Portfolio Management LLC | 1,330,710 | $20.4M | 0.0% | +40,454 |
| Two Sigma Investments, LP | 1,207,250 | $18.5M | 0.0% | +1,091,151 |
| Geode Capital Management, LLC | 1,204,150 | $18.5M | 0.0% | +57,426 |
| Citadel Advisors LLC | 1,200,737 | $18.4M | 0.0% | +848,560 |
| Algert Global LLC | 1,110,889 | $17.1M | 0.2% | +667,492 |
| D. E. Shaw & Co., Inc. | 1,096,509 | $16.8M | 0.0% | +998,114 |
| Goldman Sachs Group Inc | 952,675 | $14.6M | 0.0% | +350,662 |
| Bank Of America Corp /de/ | 910,460 | $14.0M | 0.0% | +108,814 |
| Morgan Stanley | 836,966 | $12.9M | 0.0% | +133,026 |
| Qube Research & Technologies Ltd | 702,057 | $10.8M | 0.0% | +504,912 |
| Squarepoint Ops LLC | 532,321 | $8.2M | 0.0% | −71,679 |
| Orbimed Advisors LLC | 524,700 | $8.1M | 0.2% | −458,900 |
| Millennium Management LLC | 504,544 | $7.7M | 0.0% | +117,734 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Janux Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARJanux Therapeutics, Inc.1
- CIK0001817713
- Employer ID (EIN)82-22891123
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address10955 Vista Sorrento Parkway, Suite 200, San Diego, CA 921301
- Phone(858) 751-44931
- Shares outstanding61,136,773 as of Aug 4, 20269
- Public float$1.1B as of Jun 30, 20253
- AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; it also attests to the company’s internal control over financial reporting3
- On EDGAR sinceJul 14, 20201
- Filings440 in all: 4 (136), 144 (87), 8-K (49), 3 (27), 10-Q (16), SC 13G/A (14), SCHEDULE 13G/A (13), SC 13D/A (12)1
All 36 form types
SC 13G (8), SCHEDULE 13G (8), 424B5 (6), DEFA14A (6), S-8 (6), 10-K (5), CORRESP (5), DEF 14A (5), 144/A (4), ARS (4), D (3), SC 13D (3), SEC STAFF LETTER (3), UPLOAD (3), 4/A (2), EFFECT (2), FWP (2), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3 (1), S-3ASR (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 28, 2026
Latest 8-K (8-K) Aug 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value per share | JANX | The Nasdaq Global Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Janux Therapeutics, Inc. names in Item 1A of its 10-K filed Feb 26, 2026: 73 risks under these headings, as written.3
- Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
- We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.
- If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates
- We are early in our development efforts and all of our product candidates and research programs other than JANX007 and JANX008 are in the preclinical development or discovery stage. We have a limited history of conducting clinical trials to test our product candidates in humans.
- Preclinical and clinical development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. JANX007, JANX008 and any other product candidate that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.
- Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
- If we experience delays in or difficulties enrolling our ongoing and planned clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.
- Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates thereby limiting the commercial potential of such product candidate.
- Interim, topline and preliminary data from our preclinical studies or clinical trials may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.
- The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.
The other 61 risks
- Even if we obtain regulatory approval for our product candidates, they will remain subject to ongoing regulatory oversight. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.
- Disruptions to the operations of the FDA, the SEC, other U.S. governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, staffing cuts or other staffing shortages, along with uncertainty regarding the potential for new initiatives, laws, regulations, policies and guidance affecting our product candidates or other aspects of our business, could materially and adversely affect our business.
- We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
- We may not be successful in our efforts to identify or discover additional product candidates in the future.
- Risks Related to Manufacturing, Commercialization and Reliance on Third Parties
- We rely on third parties to conduct, supervise, and monitor our ongoing and planned clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.
- We contract with third parties for the manufacturing and supply of certain of our product candidates for use in preclinical testing and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.
- Manufacturing our product candidates is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
- Changes in methods of product candidate manufacturing may result in additional costs or delays.
- Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, cancer treatment centers, healthcare payors and others in the medical community necessary for commercial success.
- We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.
- Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
- Relevant regulatory exclusivities may not be granted or, if granted, may be limited.
- The market opportunity for our product candidates may be relatively small as it will be limited to those patients who are ineligible for or have failed prior treatments and our estimates of the prevalence of our target patient populations may be inaccurate.
- Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
- If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.
- Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.
- Risks Related to Our Collaborations and Other Strategic Agreements
- Our existing collaborations with Merck and BMS are important to our business. If our collaborators cease development efforts under our existing or future collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.
- We may not realize the benefits of any acquisitions, collaborations, in-license or strategic alliances that we enter into.
- We may wish to form additional collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.
- Risks Related to Our Industry and Business Operations
- Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
- We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.
- We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
- We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
- We face substantial competition, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us.
- Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
- Epidemic diseases could adversely impact our business, including our ongoing and planned clinical trials, supply chain and business development activities.
- Risks Related to Government Regulation
- Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to U.S. federal and state, EU, or foreign jurisdictions’ healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
- Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates.
- International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
- Risks Related to Our Intellectual Property
- If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
- We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.
- Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
- We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
- We are currently a party to an in-license agreement under which we were granted rights to manufacture certain components of our product candidates. If we breach our obligations under this and future license agreements, we may be required to pay damages, lose our rights to these technologies or both, which would adversely affect our business and prospects.
- In the future, we may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated.
- If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
- We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
- Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
- We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- We may rely on trade secret and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Risks Related to the Securities Market and Ownership of Our Common Stock
- The price of our common stock could be subject to volatility related or unrelated to our operations.
- Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
- If there are substantial sales of shares of our common stock, the market price of our common stock could decline.
- Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.
- General Risk Factors
- We incur significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives.
- If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
- Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
- Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.
- Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
- Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
- Inflation may adversely affect us by increasing our costs.
- If our internal information technology systems or sensitive information, or those of third parties with whom we work (such as CROs or other contractors or consultants), are or were compromised, we could experience adverse consequences from such compromise, including but not limited to, a material disruption of our product candidates’ development programs, regulatory investigations or actions, litigation, fines and penalties, reputational harm, loss of revenue or profits, and other adverse consequences.
- We or the third parties upon whom we depend on may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
- We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.
Legal proceedings
From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARWilliam Go, Chief Medical Officer
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARWayne Godfrey, Chief Medical Officer
- 21
- 22SEC EDGAREric Dobmeier, Board member
- 23SEC EDGARNatasha Hernday, Board member
- 24SEC EDGARWinston Kung, Board member
- 25SEC EDGARJake Simson, Board member
- 26SEC EDGARJay Lichter, Board member
- 27SEC EDGARPeter A. Thompson, Board member
- 28SEC EDGARPeter Kolchinsky, Board member
- 29SEC EDGARSheila Gujrathi, Board member
- 30SEC EDGARStefan Heller, Board member
- 31SEC EDGARVickie L. Capps, Board member
- 32SEC EDGARAlana B. McNulty, Board member
- 33SEC EDGARRonald W. Barrett, Board member
- 34SEC EDGARResults of operations
- 35SEC EDGAROther events
- 36SEC EDGARShareholder vote
- 37SEC EDGARResults of operations
- 38SEC EDGARExecutive or director change
- 39SEC EDGARResults of operations
- 40
- 41SEC EDGARResults of operations
- 42SEC EDGARExecutive or director change
- 43SEC EDGARResults of operations
- 44SEC EDGARShareholder vote
- 45SEC EDGARResults of operations
- 46NasdaqNasdaq calendar
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65